Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340.

Literature DB >> 3004944

Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340.

Abstract

The Epstein-Barr virus membrane antigen gene gp340 was isolated, inserted into several strains of vaccinia virus and expressed under the control of a vaccinia virus promoter. The EBV-derived protein which was produced by the recombinant vaccinia viruses was heavily glycosylated, readily labelled with threonine, could be detected at the surface of infected cells and had a mol. wt. of approximately 340 kd, all of which are properties of the authentic gp340. Polyclonal rabbit antisera against gp340 and an EBV-neutralising anti-gp340 monoclonal antibody both recognised cells infected with the recombinant vaccinia viruses. Moreover, rabbits vaccinated with one of the recombinants produced antibodies that recognised EBV-containing lymphoblastoid cells and neutralised EBV.

Entities: Chemical

Mesh：

Substances：

Year: 1985 PMID： 3004944 PMCID： PMC554647 DOI： 10.1002/j.1460-2075.1985.tb04070.x

Source DB: PubMed Journal: EMBO J ISSN： 0261-4189 Impact factor: 11.598

42 in total

1. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors: J V PULVERTAFT
Journal: J Clin Pathol Date: 1965-05 Impact factor: 3.411

2. Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates.

Authors: S M Franklin; J R North; A J Morgan; M A Epstein
Journal: J Gen Virol Date: 1981-04 Impact factor: 3.891

3. Extension of the transcriptional and translational map of the left end of the vaccinia virus genome to 21 kilobase pairs.

Authors: J A Cooper; R Wittek; B Moss
Journal: J Virol Date: 1981-09 Impact factor: 5.103

4. Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments.

Authors: J R Arrand; L Rymo; J E Walsh; E Björck; T Lindahl; B E Griffin
Journal: Nucleic Acids Res Date: 1981-07-10 Impact factor: 16.971

5. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors: D A Thorley-Lawson; K Geilinger
Journal: Proc Natl Acad Sci U S A Date: 1980-09 Impact factor: 11.205

6. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors: J Vieira; J Messing
Journal: Gene Date: 1982-10 Impact factor: 3.688

7. Visualization of minute centers of viral infection in unfixed cell cultures by an enzyme-linked antibody assay.

Authors: K O Smith; W L Kennell; D L Lamm
Journal: J Immunol Methods Date: 1981 Impact factor: 2.303

8. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors: G J Hoffman; S G Lazarowitz; S D Hayward
Journal: Proc Natl Acad Sci U S A Date: 1980-05 Impact factor: 11.205

9. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.

Authors: J R North; A J Morgan; M A Epstein
Journal: Int J Cancer Date: 1980-08 Impact factor: 7.396

10. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA.

Authors: J P Weir; G Bajszár; B Moss
Journal: Proc Natl Acad Sci U S A Date: 1982-02 Impact factor: 11.205

17 in total

1. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors: L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal: J Virol Date: 1990-12 Impact factor: 5.103

2. Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment.

Authors: M Mackett; M J Conway; J R Arrand; R S Haddad; L M Hutt-Fletcher
Journal: J Virol Date: 1990-06 Impact factor: 5.103

3. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.

Authors: M E Perkus; K Limbach; E Paoletti
Journal: J Virol Date: 1989-09 Impact factor: 5.103

4. Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors: Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal: J Virol Date: 1987-06 Impact factor: 5.103

Review 5. Use of vaccinia virus to express biopharmaceutical products.

Authors: D E Hruby; G Thomas
Journal: Pharm Res Date: 1987-04 Impact factor: 4.200

6. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors: J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal: J Virol Date: 1988-12 Impact factor: 5.103

7. Varicella-zoster virus as a live vector for the expression of foreign genes.

Authors: R S Lowe; P M Keller; B J Keech; A J Davison; Y Whang; A J Morgan; E Kieff; R W Ellis
Journal: Proc Natl Acad Sci U S A Date: 1987-06 Impact factor: 11.205

8. Expression of Mycobacterium tuberculosis and Mycobacterium leprae proteins by vaccinia virus.

Authors: J Lyons; C Sinos; A Destree; T Caiazzo; K Havican; S McKenzie; D Panicali; A Mahr
Journal: Infect Immun Date: 1990-12 Impact factor: 3.441

9. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors: J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal: Infect Immun Date: 1996-09 Impact factor: 3.441

10. The live vector approach-viruses.

Authors: M Mackett
Journal: World J Microbiol Biotechnol Date: 1991-03 Impact factor: 3.312